Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMZNJFU)

• Drug Name: UCL1684 Drug Info
• Synonyms: UCL-1684

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 656733
  ChEBI ID: CHEBI:35040
  TTD Drug ID: DMZNJFU

Molecule-Related Drug Atlas

Drug(s) Targeting Calcium-activated potassium channel KCa2.3 (KCNN3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
dequalinium	DMXM19W	Myelopathy	8B42	Clinical trial	[5]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[2]
EBIO	DMPKI0N	Discovery agent	N.A.	Investigative	[2]
DC-EBIO	DM2T5OV	Discovery agent	N.A.	Investigative	[6]
UCL1848	DM2CN0A	Discovery agent	N.A.	Investigative	[4]
apamin	DMYNBK5	Discovery agent	N.A.	Investigative	[4]
CyPPA	DM64L9I	Discovery agent	N.A.	Investigative	[7]

Drug(s) Targeting Calcium-activated potassium channel KCa2.1 (KCNN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
dequalinium	DMXM19W	Myelopathy	8B42	Clinical trial	[3]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[2]
EBIO	DMPKI0N	Discovery agent	N.A.	Investigative	[2]
UCL1848	DM2CN0A	Discovery agent	N.A.	Investigative	[8]
apamin	DMYNBK5	Discovery agent	N.A.	Investigative	[3]

Drug(s) Targeting Calcium-activated potassium channel KCa2.2 (KCNN2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
dequalinium	DMXM19W	Myelopathy	8B42	Clinical trial	[9]
zoxazolamine	DM70TKB	Multiple myeloma	2A83	Terminated	[10]
[14C]TEA	DM6SFYH	Discovery agent	N.A.	Investigative	[2]
EBIO	DMPKI0N	Discovery agent	N.A.	Investigative	[2]
DC-EBIO	DM2T5OV	Discovery agent	N.A.	Investigative	[11]
UCL1848	DM2CN0A	Discovery agent	N.A.	Investigative	[12]
apamin	DMYNBK5	Discovery agent	N.A.	Investigative	[13]
CyPPA	DM64L9I	Discovery agent	N.A.	Investigative	[7]

Drug(s) Affected By Small conductance calcium-activated potassium channel protein 1 (KCNN1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[14]
Tubocurarine	DMBZIVP	Anaesthesia	9A78.6	Approved	[3]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[15]
Carbamazepine	DMZOLBI	Epilepsy	8A60-8A68	Approved	[16]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[17]
acetaldehyde	DMJFKG4	Discovery agent	N.A.	Investigative	[18]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium-activated potassium channel KCa2.1 (KCNN1)	TT9R6BE	KCNN1_HUMAN	Blocker (channel blocker)	[2]
Calcium-activated potassium channel KCa2.2 (KCNN2)	TT2T5M0	KCNN2_HUMAN	Blocker (channel blocker)	[3]
Calcium-activated potassium channel KCa2.3 (KCNN3)	TT9JH25	KCNN3_HUMAN	Blocker (channel blocker)	[4]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Small conductance calcium-activated potassium channel protein 1 (KCNN1)	OT87X2EH	KCNN1_HUMAN	Gene/Protein Processing	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2320).
• [2] Small conductance calcium-activated potassium channels: from structure to function. Prog Neurobiol. 2010 Jul;91(3):242-55.
• [3] Pharmacological characterization of small-conductance Ca(2+)-activated K(+) channels stably expressed in HEK 293 cells. Br J Pharmacol. 2000 Mar;129(5):991-9.
• [4] SK3 is an important component of K(+) channels mediating the afterhyperpolarization in cultured rat SCG neurones. J Physiol. 2001 Sep 1;535(Pt 2):323-34.
• [5] Pharmacological characterisation of the human small conductance calcium-activated potassium channel hSK3 reveals sensitivity to tricyclic antidepressants and antipsychotic phenothiazines. Neuropharmacology. 2001 May;40(6):772-83.
• [6] Modulators of small- and intermediate-conductance calcium-activated potassium channels and their therapeutic indications. Curr Med Chem. 2007;14(13):1437-57.
• [7] Selective positive modulation of the SK3 and SK2 subtypes of small conductance Ca2+-activated K+ channels. Br J Pharmacol. 2007 Jul;151(5):655-65.
• [8] The pharmacology of hSK1 Ca2+-activated K+ channels expressed in mammalian cell lines. Br J Pharmacol. 2000 Feb;129(4):627-30.
• [9] Block of rat brain recombinant SK channels by tricyclic antidepressants and related compounds. Eur J Pharmacol. 2000 Jul 28;401(1):1-7.
• [10] Modulation of recombinant small-conductance Ca(2+)-activated K(+) channels by the muscle relaxant chlorzoxazone and structurally related compounds. J Pharmacol Exp Ther. 2001 Mar;296(3):683-9.
• [11] Specific enhancement of SK channel activity selectively potentiates the afterhyperpolarizing current I(AHP) and modulates the firing properties of ... J Biol Chem. 2005 Dec 16;280(50):41404-11.
• [12] Calcium-activated potassium channels sustain calcium signaling in T lymphocytes. Selective blockers and manipulated channel expression levels. J Biol Chem. 2001 Apr 13;276(15):12249-56.
• [13] SK2 encodes the apamin-sensitive Ca(2+)-activated K(+) channels in the human leukemic T cell line, Jurkat. FEBS Lett. 2000 Mar 10;469(2-3):196-202.
• [14] Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
• [15] Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
• [16] Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
• [17] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [18] Transcriptome profile analysis of saturated aliphatic aldehydes reveals carbon number-specific molecules involved in pulmonary toxicity. Chem Res Toxicol. 2014 Aug 18;27(8):1362-70.